What is Bone Biologics Corp's earnings per share (EPS)?

Bone Biologics Corp (BBLG) reported diluted earnings per share of -$2.65 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bone Biologics Corp (BBLG) Financials

BBLG

FY2025 annual

Revenue Not reported for FY2025

Net Income -$3.1M +24.4% YoY

EPS (Diluted) -$2.65 YoY not available

Operating Cash Flow -$2.7M +34.8% YoY

Market Cap $1.3M as of Oct 12, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.3x on $3.9M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BBLG SEC filings page.

This page shows Bone Biologics Corp (BBLG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BBLG FY2025 2026-10-03

The company remains a development-stage operation: losses and cash use are narrowing as research spending falls, while financing supports a lightly indebted balance sheet.

Operating cash use narrowed from $9.6M in FY2023 to $2.7M in FY2025, alongside a much smaller development budget. R&D fell from $6.9M to $1.1M over the same period, indicating that the improved cash profile reflects reduced development spending more than demonstrated operating scale.

In FY2025, operating cash flow used $2.7M compared with a net loss of $3.1M. That close pairing leaves little evidence in these figures of a large noncash gap between accounting losses and cash consumption.

Assets rose from $3.9M in FY2024 to $5.8M in FY2025 while financing cash flow remained positive, indicating expansion funded outside operations. Liabilities remained near $0.4M and the current ratio reached 13.8x, while reported liquidity equaled 23.8 months of the latest annual operating outflow.

Financial Health Signals

Financial health score not available

Bone Biologics Corp does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

4/6

Bone Biologics Corp passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Bone Biologics Corp reported a net loss of $3.1M while operations used $2.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$774K

YoY-4.5%

QoQ-1.0%

Bone Biologics Corp reported -$774K in net income in Q2 2026. This represents a decrease of 4.5% from the same quarter a year earlier. Against the prior quarter it is down 1.0%.

EPS (Diluted)

-$0.43

QoQ0.0%

Bone Biologics Corp earned -$0.43 per diluted share (EPS) in Q2 2026. It is unchanged from the prior quarter.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$4.0M

YoY-39.3%

QoQ-11.0%

5Y CAGR+290.5%

Bone Biologics Corp held $4.0M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

QoQ+53.5%

5Y CAGR-38.2%

Bone Biologics Corp had 3M shares outstanding in Q2 2026. Against the prior quarter it is up 53.5%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-19.7%

YoY-8.5pp

QoQ-3.3pp

Bone Biologics Corp's ROE was -19.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 8.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.3 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$309K

YoY+61.1%

QoQ+118.0%

Bone Biologics Corp invested $309K in research and development in Q2 2026. This represents an increase of 61.1% from the same quarter a year earlier. Against the prior quarter it is up 118.0%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

BBLG Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BBLG quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$1.1B	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$1.1M-50.2%	$2.1M-69.2%	$6.9M+337.4%	$1.6M+1824.9%	$82K-75.9%	$341K	N/A	$104K-92.6%	$1.4M	N/A	$3.7M+488.0%	$624K+231.2%	$188K	N/A	N/A
SG&A Expenses	N/A	$2.2M+4.1%	$2.1M-17.1%	$2.5M+20.8%	$2.1M+104.3%	$1.0M+110.8%	$484K	N/A	$2.7M-32.1%	$4.0M	N/A	N/A	$1.5M	N/A	N/A	N/A
Operating Income	N/A	-$3.2M+23.3%	-$4.2M+55.3%	-$9.4M-157.2%	-$3.7M-232.3%	-$1.1M-33.7%	-$825K	N/A	-$2.8M-6.3%	-$2.6M	N/A	N/A	-$3.0M	N/A	N/A	N/A
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$2.8M-6.3%	-$2.6M	N/A	N/A	-$3.0M	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	$2K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$106K-92.5%	$1.4M+242.6%	$409K	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	$2K0.0%	$2K-0.2%	$2K-7.3%	$2K+8.1%	$2K-28.7%	$2K-74.6%	$9K+452.5%	$2K+100.0%	$800	N/A	N/A
Net Income	N/A	-$3.1M+24.4%	-$4.1M+54.0%	-$8.9M-502.8%	-$1.5M+7.8%	-$1.6M+11.7%	-$1.8M	N/A	-$4.4M	N/A	N/A	N/A	-$4.4M	N/A	N/A	-$938K
EPS (Basic)	N/A	-$2.65+90.8%	-$28.96+14.8%	-$34.01-9.2%	-$31.15-8800.0%	-$0.35	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$2.65	-$28.96	-$34.01	-$31.15	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	1M	252,960	263,137	47,658	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$309K+61.1%	$142K-66.6%	N/A	$188K-56.3%	$192K-45.3%	$424K+72.4%	N/A	$430K-72.7%
SG&A Expenses	$499K-10.3%	$663K+7.9%	N/A	$527K+1.2%	$556K+21.2%	$615K-6.5%	N/A	$521K+3.0%
Operating Income	-$808K-8.0%	-$805K+22.5%	N/A	-$715K+24.8%	-$748K+7.6%	-$1.0M-14.9%	N/A	-$951K+54.3%
Net Income	-$774K-4.5%	-$766K+24.7%	N/A	-$667K+29.1%	-$741K+5.5%	-$1.0M-17.5%	N/A	-$941K+51.0%
EPS (Basic)	-$0.43+67.7%	-$0.43+77.6%	-$0.14-800.0%	-$0.37+97.4%	-$1.33+66.9%	-$1.92-46.6%	$0.02+100.1%	-$14.21-190.0%
EPS (Diluted)	-$0.43	-$0.43	-$0.14	-$0.37	-$1.33	-$1.92	$0.02	-$14.21
Diluted Shares (Avg)	2M	2M	N/A	2M	557,787	530,618	N/A	292,321

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax.

BBLG Balance Sheet

BBLG quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$5.8M+50.1%	$3.9M+3.3%	$3.7M-56.0%	$8.5M+27.3%	$6.7M	$0-100.0%	$31K-97.0%	$1.0M+30.8%	$796K+13.5%	$701K-54.7%	$1.5M-59.5%	$3.8M+4277.1%	$87K+18475.5%	$470+100.0%	-$3.9M
Current Assets	$5.8M+50.1%	$3.9M+3.3%	$3.7M-56.0%	$8.5M	N/A	N/A	$31K-97.0%	$1.0M+30.8%	$796K+13.5%	$701K-54.5%	$1.5M-59.6%	$3.8M+4263.7%	$87K	N/A	N/A
Cash & Equivalents	$5.3M+60.4%	$3.3M+9.9%	$3.0M-59.9%	$7.5M+12.9%	$6.7M	N/A	$24K-97.5%	$955K+38.4%	$690K+11.3%	$620K-44.4%	$1.1M-58.1%	$2.7M+172942.7%	$2K	N/A	N/A
Short-Term Investments	$0	$0	$0	$0	$0	N/A	$0	$0	$0	$0	$0	$0	$0	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	N/A	$0	$0	$0	$0	$0	$0	$0	N/A	N/A
Total Liabilities	$419K+10.8%	$378K-54.6%	$831K-67.4%	$2.5M+2450.2%	$100K-99.3%	$13.7M+15.1%	$11.9M+23.4%	$9.6M+4.9%	$9.2M+1.4%	$9.1M+57.8%	$5.7M-23.6%	$7.5M+32.0%	$5.7M+21.8%	$4.7M+15322.6%	$30K
Current Liabilities	$419K+10.8%	$378K-54.6%	$831K-67.4%	$2.5M+2450.2%	$100K-99.3%	$13.7M+2267.1%	$578K-94.0%	$9.6M+902.2%	$962K-36.0%	$1.5M-30.0%	$2.1M-44.6%	$3.9M-32.0%	$5.7M	N/A	N/A
Non-Current Liabilities	$0	$0	$0	$0	$0	$0-100.0%	$11.3M	$0-100.0%	$8.2M+8.8%	$7.6M+110.1%	$3.6M-1.3%	$3.6M	$0	N/A	N/A
Total Equity	$5.4M+54.4%	$3.5M+19.9%	$2.9M-51.1%	$5.9M-9.6%	$6.6M+148.0%	-$13.7M-15.4%	-$11.9M-38.0%	-$8.6M-2.4%	-$8.4M-0.4%	-$8.4M-99.2%	-$4.2M-13.5%	-$3.7M+34.1%	-$5.6M-19.9%	-$4.7M-18.1%	-$4.0M
Retained Earnings	-$88.1M-3.7%	-$85.0M-5.1%	-$80.9M-12.4%	-$72.0M-2.1%	-$70.5M-2.3%	-$68.9M-2.7%	-$67.0M-5.4%	-$63.6M-7.5%	-$59.2M-13.5%	-$52.1M-101.2%	-$25.9M-115.3%	-$12.0M-58.1%	-$7.6M-12536.9%	$61K+210.7%	-$55K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$4.4M-36.6%	$5.0M+57.5%	$5.8M+50.1%	$6.4M+56.2%	$7.0M+119.3%	$3.2M-17.6%	$3.9M+3.3%	$4.1M-18.3%
Current Assets	$4.4M-36.6%	$5.0M+57.5%	$5.8M+50.1%	$6.4M+56.2%	$7.0M+119.3%	$3.2M-17.6%	$3.9M+3.3%	$4.1M
Cash & Equivalents	$4.0M-39.3%	$4.5M+64.9%	$5.3M+60.4%	$6.0M+69.6%	$6.6M+184.7%	$2.7M-14.9%	$3.3M+9.9%	$3.6M-19.9%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$512K+26.1%	$309K+23.2%	$419K+10.8%	$334K+22.3%	$406K+42.8%	$251K+52.6%	$378K-54.6%	$273K-76.9%
Current Liabilities	$512K+26.1%	$309K+23.2%	$419K+10.8%	$334K+22.3%	$406K+42.8%	$251K+52.6%	$378K-54.6%	$273K-76.9%
Non-Current Liabilities	$0	$0	$0	$0	$0	$0	$0	$0
Total Equity	$3.9M-40.5%	$4.7M+60.4%	$5.4M+54.4%	$6.0M+58.6%	$6.6M+126.8%	$2.9M-20.8%	$3.5M+19.9%	$3.8M0.0%
Retained Earnings	-$89.7M-3.3%	-$88.9M-3.3%	-$88.1M-3.7%	-$87.4M-4.7%	-$86.8M-5.1%	-$86.0M-5.2%	-$85.0M-5.1%	-$83.5M-5.2%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

BBLG Cash Flow Statement

BBLG quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$2.6M	-$2.7M+34.8%	-$4.1M+56.8%	-$9.6M-167.9%	-$3.6M-190.3%	-$1.2M-187.8%	-$427K	N/A	-$4.1M-23.3%	-$3.3M	N/A	-$3.5M-28.7%	-$2.8M	N/A	N/A	-$4K
Depreciation & Amortization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$50-47.9%	$960.0%	$96-86.3%	$700-84.3%	$4K+1489.6%	$280	N/A	N/A	N/A
Stock-Based Compensation	N/A	$256K+35.8%	$189K+23.7%	$153K-42.8%	$267K+28.8%	$207K	N/A	$50K-90.4%	$517K-68.0%	$1.6M-61.0%	$4.1M+12.0%	$3.7M+1341.9%	$257K	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$504-95.8%	$12K	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$3.5M-28.1%	-$2.8M	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$504-102.0%	$25K	N/A	N/A	N/A
Financing Cash Flow	N/A	$4.7M+6.3%	$4.4M-12.3%	$5.0M+13.9%	$4.4M-44.0%	$7.9M+1862.3%	$403K	N/A	$4.4M+28.5%	$3.4M	N/A	$2.0M-62.9%	$5.4M	N/A	N/A	$4K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$518K-13.0%	-$804K+13.2%	-$715K+47.2%	-$591K-3.4%	-$459K+48.8%	-$926K+28.9%	-$1.4M+32.9%	-$572K+77.6%
Stock-Based Compensation	N/A	$24K-53.6%	N/A	N/A	N/A	$51K-3.9%	N/A	N/A
Financing Cash Flow	N/A	N/A	$0-100.0%	$0-100.0%	$4.4M+1455683.3%	$348K-76.9%	$1.1M+87.9%	$1.8M

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

BBLG Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BBLG quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Margin	N/A	N/A	N/A	N/A	N/A	-0.1%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	-0.2%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-57.8%+60.2pp	-118.1%+189.8pp	-307.9%-282.9pp	-25.0%-0.5pp	-24.5%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-53.6%+52.9pp	-106.5%+132.9pp	-239.4%-221.9pp	-17.5%+6.6pp	-24.1%	N/A	N/A	-425.7%	N/A	N/A	N/A	-115.8%	N/A	N/A	23.9%
Current Ratio	13.85+3.6x	10.22+5.7x	4.50+1.2x	3.33	N/A	N/A	0.05-0.1x	0.11-0.7x	0.83+0.4x	0.47-0.3x	0.72-0.3x	0.98+1.0x	0.02	N/A	N/A
Debt-to-Equity	0.080.0x	0.11-0.2x	0.29-0.1x	0.43+0.4x	0.02	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-19.7%-8.5pp	-16.4%+18.5pp	N/A	-11.1%+13.7pp	-11.2%+15.7pp	-34.9%-11.4pp	N/A	-24.8%+25.8pp
Return on Assets	-17.4%-6.9pp	-15.4%+16.8pp	N/A	-10.5%+12.6pp	-10.6%+14.0pp	-32.2%-9.6pp	N/A	-23.1%+15.4pp
Current Ratio	8.67-8.6x	16.09+3.5x	13.85+3.6x	19.00+4.1x	17.24+6.0x	12.59-10.7x	10.22+5.7x	14.87
Debt-to-Equity	0.13+0.1x	0.070.0x	0.080.0x	0.060.0x	0.060.0x	0.090.0x	0.11-0.2x	0.07-0.2x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Bone Biologics Corp BBLG	FY2025	N/A	-$3.1M	N/A	$1.3M	—
Nuwellis, Inc. NUWE	FY2025	$8.3M	-$17.5M	N/A	$2.2M	46/100
Catheter Precision, Inc. VTAK	FY2025	$819K	-$17.2M	N/A	$549K	—
VENUS CONCEPT INC VERO	FY2024	$64.8M	-$47.0M	-72.5%	$2.1M	—
NanoVibronix, Inc. NAOV	FY2025	$2.6M	-$18.2M	N/A	$4.4M	28/100
Tivic Health Systems, Inc. TIVC	FY2025	N/A	-$8.9M	N/A	$4.0M	—

Where Bone Biologics Corp Ranks

Frequently Asked Questions

Is Bone Biologics Corp profitable?

No, Bone Biologics Corp (BBLG) reported a net income of -$3.1M in fiscal year 2025.

What is Bone Biologics Corp's return on equity (ROE)?

Bone Biologics Corp (BBLG) has a return on equity of -57.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bone Biologics Corp's operating cash flow?

Bone Biologics Corp (BBLG) recorded an outflow of $2.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Bone Biologics Corp's total assets?

Bone Biologics Corp (BBLG) had $5.8M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Bone Biologics Corp spend on research and development?

Bone Biologics Corp (BBLG) invested $1.1M in research and development during fiscal year 2025.

How many shares does Bone Biologics Corp have outstanding?

Bone Biologics Corp (BBLG) had 2M shares outstanding as of fiscal year 2025.

What is Bone Biologics Corp's current ratio?

Bone Biologics Corp (BBLG) had a current ratio of 13.85 as of fiscal year 2025, which is generally considered healthy.

What is Bone Biologics Corp's debt-to-equity ratio?

Bone Biologics Corp (BBLG) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bone Biologics Corp's return on assets (ROA)?

Bone Biologics Corp (BBLG) had a return on assets of -53.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bone Biologics Corp's P/E ratio?

Bone Biologics Corp (BBLG) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $1.3M as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Bone Biologics Corp's price-to-sales ratio?

Bone Biologics Corp (BBLG) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $1.3M as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Bone Biologics Corp's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Bone Biologics Corp (BBLG) held $5.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $2.7M over that year. Dividing the one by the other, the reported balance equals about 24 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Bone Biologics Corp's Piotroski F-Score?

Bone Biologics Corp (BBLG) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bone Biologics Corp's earnings high quality?

Bone Biologics Corp (BBLG) reported a net loss of $3.1M while operations used $2.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.